Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Citius Pharmaceuticals

14/02/2024 23:57

* Citius Pharmaceuticals Inc  CTXR.OQ  reported a quarterly
adjusted loss of 6 cents​​ per share for the quarter ended in
December.  The lone analyst forecast for the quarter was
for earnings of 13 cents per share. 
    * Reported revenue was zero​; analysts expected $21.30
million. 
    * Citius Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 6 cents​.
    * The company reported a quarterly loss of $9.23 million.
    * Citius Pharmaceuticals Inc shares had fallen by 10.1% this
quarter.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4.00 
This summary was machine generated from LSEG data February 14 at
11:57 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      0.13           -0.06          Missed
 Sep. 30 2023      -0.02          -0.08          Missed
 Jun. 30 2023      -0.05          -0.06          Missed
 Mar. 31 2023      -0.03          -0.07          Missed